The insider sales are too small to be informative on their own, but the cluster's timing with earnings and the massive shelf registration signals that insiders are not buying the dip. The $400M shelf overhang and going-concern warning dominate the narrative. Monitor for any ATM drawdown or further insider selling; the stock is likely to remain under pressure until the capital raise is resolved.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $7.14entry
- T+1 · 6mo ago +4.62%α +5.27% · $7.47
- T+5 · 6mo ago +25.63%α +24.01% · $8.97
- T+20 · 5mo ago +27.45%α +25.87% · $9.10
- T+60 · 3mo ago −71.57%α −76.42% · $2.03
Price Chart
How similar events traded
Executive Summary
Karyopharm's CEO, CAO, and EVP/CLO sold a total of $23K in open-market shares on May 14, 2026, the same day the company reported Q1 earnings that beat EPS consensus by 29% but included a going-concern warning and a $400M shelf filing. The sales are trivial at 0.01% of market cap and likely liquidity-driven following equity grants, but the cluster's timing with earnings and the massive dilution overhang from the shelf registration creates a bearish context.
Key Financial Metrics
Key Facts
- CEO Richard Paulson sold 2,203 shares at $9.50 for $20,929 on May 14, 2026.
- CAO Kristin Abate sold 53 shares at $9.50 for $504 on May 14, 2026.
- EVP/CLO Michael Mano sold 266 shares at $9.50 for $2,527 on May 14, 2026.
- Total open-market sales: $23,959, representing 0.01% of KPTI's $201M market cap.
- All three insiders also received non-cash equity grants (shares) on May 13, 2026, totaling 5,741 shares at $0.
- The sales occurred one day after Q1 2026 earnings (revenue $35.1M, net loss -$22.4M, EPS beat consensus by 29%) and 11 days after a $400M shelf registration was filed.
- The $400M shelf (including a $100M ATM) represents ~200% of market cap; the company has a going-concern warning and cash runway only into late Q3 2026.
- The insider sales are trivial in dollar terms but cluster with earnings and a dilutive capital raise, per cross-filing actuarial amplifiers.
Financial Impact
Open-market sales of $23,959 (0.01% of market cap) are immaterial in isolation, but the context of a $400M shelf (200% dilution) and going-concern warning is highly material.
Risk Factors
- Massive dilution from the $400M shelf registration (200% of market cap) if fully utilized.
- Going-concern warning with cash runway only into late Q3 2026, forcing a dilutive capital raise.
- Phase 3 SENTRY myelofibrosis trial missed a co-primary endpoint, reducing pipeline optionality.
- Insider sales, though small, may signal lack of confidence in the near-term outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KPTI-1778875595275 |
Track record
30 reports on KPTI
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers